» Articles » PMID: 34636997

How to Fix a Broken Protein: Restoring Function to Mutant Human Cystathionine β-synthase

Overview
Journal Hum Genet
Specialty Genetics
Date 2021 Oct 12
PMID 34636997
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Inborn errors of metabolism (IEM) comprise a large class of recessive genetic diseases involving disorders of cellular metabolism that tend to be caused by missense mutations in which a single incorrect amino acid is substituted in the polypeptide chain. Cystathionine beta-synthase (CBS) deficiency is an example of an IEM that causes large elevations of blood total homocysteine levels, resulting in phenotypes in several tissues. Current treatment strategies involve dietary restriction and vitamin therapy, but these are only partially effective and do not work in all patients. Over 85% of the described mutations in CBS-deficient patients are missense mutations in which the mutant protein fails to fold into an active conformation. The ability of CBS to achieve an active conformation is affected by a variety of intracellular protein networks including the chaperone system and the ubiquitin/proteasome system, collectively referred to as the proteostasis network. Proteostasis modulators are drugs that perturb various aspects of these networks. In this article, we will review the evidence that modulation of the intracellular protein folding environment can be used as a potential therapeutic strategy to treat CBS deficiency and discuss the pros and cons of such a strategy.

Citing Articles

Deciphering pathophysiological mechanisms underlying cystathionine beta-synthase-deficient homocystinuria using targeted metabolomics, liver proteomics, sphingolipidomics and analysis of mitochondrial function.

Majtan T, Olsen T, Sokolova J, Krijt J, Krizkova M, Ida T Redox Biol. 2024; 73:103222.

PMID: 38843767 PMC: 11190558. DOI: 10.1016/j.redox.2024.103222.


Architecture and regulation of filamentous human cystathionine beta-synthase.

McCorvie T, Adamoski D, Machado R, Tang J, Bailey H, Ferreira D Nat Commun. 2024; 15(1):2931.

PMID: 38575566 PMC: 10995199. DOI: 10.1038/s41467-024-46864-x.


Genetic and Pharmacological Modulation of Cellular Proteostasis Leads to Partial Functional Rescue of Homocystinuria-Causing Cystathionine-Beta Synthase Variants.

Collard R, Majtan T Mol Cell Biol. 2023; 43(12):664-674.

PMID: 38051092 PMC: 10761163. DOI: 10.1080/10985549.2023.2284147.


Examination of two different proteasome inhibitors in reactivating mutant human cystathionine β-synthase in mice.

Gupta S, Lee H, Wang L, Kruger W PLoS One. 2023; 18(6):e0286550.

PMID: 37319242 PMC: 10270616. DOI: 10.1371/journal.pone.0286550.


HS biogenesis by cystathionine beta-synthase: mechanism of inhibition by aminooxyacetic acid and unexpected role of serine.

Petrosino M, Zuhra K, Kopec J, Hutchin A, Szabo C, Majtan T Cell Mol Life Sci. 2022; 79(8):438.

PMID: 35864237 PMC: 9304066. DOI: 10.1007/s00018-022-04479-9.


References
1.
Applegarth D, Toone J, Lowry R . Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics. 2000; 105(1):e10. DOI: 10.1542/peds.105.1.e10. View

2.
Aral B, Coude M, London J, Aupetit J, Chasse J, Zabot M . Two novel mutations (K384E and L539S) in the C-terminal moiety of the cystathionine beta-synthase protein in two French pyridoxine-responsive homocystinuria patients. Hum Mutat. 1997; 9(1):81-2. DOI: 10.1002/(SICI)1098-1004(1997)9:1<81::AID-HUMU18>3.0.CO;2-L. View

3.
Balch W, Morimoto R, Dillin A, Kelly J . Adapting proteostasis for disease intervention. Science. 2008; 319(5865):916-9. DOI: 10.1126/science.1141448. View

4.
Banerjee R, Zou C . Redox regulation and reaction mechanism of human cystathionine-beta-synthase: a PLP-dependent hemesensor protein. Arch Biochem Biophys. 2004; 433(1):144-56. DOI: 10.1016/j.abb.2004.08.037. View

5.
Barber G, Spaeth G . The successful treatment of homocystinuria with pyridoxine. J Pediatr. 1969; 75(3):463-78. DOI: 10.1016/s0022-3476(69)80274-x. View